Roche
NEWS
Roche intends to hold two global meetings with members of the DMD community to provide the stakeholders with as much information as possible.
Under the terms of the deal, Roche will pay Dicerna $200 million upfront and up to another $1.47 billion for various development, regulatory and commercial milestones.
This marks the eighth such extension for the deal.
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
Last week was busy for clinical trial news. Here’s a look.
Roche announced results from its Phase III PEMPHIX trial evaluated MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris.
Roche Vice Chairman Andre Hoffman is warning that short-term thinking is killing the planet and that corporations must engage in long-term sustainable strategies that limit any environmental harm and can help reverse some of the damage that’s already been done.
JOBS
IN THE PRESS